Gapping up
In reaction to earnings/guidance:
- QRVO +6.4%, ST +3.6%, GLW +2.1% (expects Q3 sales to grow by a low-teen percentage sequentially vs high-single digit consensus), PHR +1.8%, HQY +1.3%
Other news:
- ITCI +68.5% (announces topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder)
- SCOR +23.1% (granted new US patent for device co-location identification)
- NNOX +17.7% (enters distribution agreement with SPI Medical for the deployment and introduction of Nanox's medical imaging services in Mexico)
- DTIL +11.4% (FDA has granted Fast Track Designation to PBCAR269A for the treatment of relapsed/refractory multiple myeloma)
- KOS +11.2% (to farm down of a portfolio of exploration assets to Shell (RDS.A) for up to $200 mln)
- BNTX +6.1% (BioNTech and Pfizer to potentially supply the EU with 200 mln doses of mRNA-based vaccine candidate against SARS-CoV-2)
- CI +3.6% (expands offerings to customers who access health coverage through the Affordable Care Act marketplace)
- TECK +2.7% (production guidance)
- PFE +1.3% (BioNTech and Pfizer to potentially supply the EU with 200 mln doses of mRNA-based vaccine candidate against SARS-CoV-2)
Analyst comments:
- SPCE +5% (upgraded to Outperform from Neutral at Credit Suisse)
- SDC +2.6% (upgraded to Peer Perform from Underperform at Wolfe Research)
- DKNG +2.5% (initiated with an Outperform at Evercore ISI)
- AZUL +2.2% (upgraded to Buy from Hold at Deutsche Bank)
- ARMK +2.1% (upgraded to Buy from Neutral at Goldman)
- VLRS +2% (upgraded to Buy from Hold at Deutsche Bank)
- INVH +1.6% (upgraded to Buy from Sell at Goldman)
- THO +1.6% (upgraded to Outperform from Market Perform at BMO Capital Markets)